BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) On April 17, 2017, Timothy A. Pratt, age 67, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Boston Scientific since February 2010, informed the Company that he will retire by the end of 2017. Mr. Pratt joined Boston Scientific in May 2008 as Executive Vice President, General Counsel and Secretary. During the next several months, Mr. Pratt intends to lead the efforts to identify his successor and assist in a seamless transition.
About BOSTON SCIENTIFIC CORPORATION (NYSE:BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Recent Trading Information
BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) closed its last trading session down -0.15 at 24.47 with 2,589,543 shares trading hands.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Recent Trading Information
BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) closed its last trading session down -0.15 at 24.47 with 2,589,543 shares trading hands.
